Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-26 @ 11:13 PM
Ignite Modification Date:
2025-12-26 @ 11:13 PM
NCT ID:
NCT00246012
Eligibility Criteria:
Inclusion Criteria:
* Histologically confirmed melanoma including ocular and mucosal
* Documented AJCC (American Joint Committee on Cancer) Stage 3 unresectable or Stage 4 melanoma (Phase 1); AJCC Stage 4 melanoma (Phase 2)
* Radiographically measurable disease or measurable skin lesions
* Prior chemotherapy for metastatic melanoma will be allowed for Phase 1, while previously untreated for melanoma by chemotherapy will be allowed for Phase 2
* Agrees to protocol-defined use of effective contraception
Exclusion Criteria:
* History of receiving murine or human/murine recombination products of human αν integrins
* Known human immunodeficiency virus (HIV) positivity and clinically important active infection
* Presence of bone metastases or malignant effusions (non-measurable lesions) and central nervous system metastases
* Prior radiation to target lesions
* Concurrent immunotherapy, biotherapy, radiotherapy, chemotherapy, or investigational therapy and therapeutic use of anticoagulation
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00246012
Study Brief:
Protocol Section:
NCT00246012